

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
**04.09.2002 Bulletin 2002/36**

(51) Int Cl.7: **A61L 29/16, A61L 29/08,**  
**A61L 31/10, A61L 31/16**

(21) Application number: **02251370.9**

(22) Date of filing: **27.02.2002**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE TR**  
 Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **27.02.2001 US 271898**

(71) Applicant: **Medtronic AVE, Inc.**  
**Santa Rosa, California 95403 (US)**

(72) Inventors:  
 • **Carlyle, Wenda**  
**Petaluma, California 94952 (US)**

• **Cheng, Peiwen**  
**Santa Rosa, California 95409 (US)**  
 • **Cafferata, Robert L**  
**Santa Rosa, California 95405 (US)**

(74) Representative: **Baker, Colin John**  
**Eric Potter Clarkson**  
**Park View House**  
**58 The Ropewalk**  
**Nottingham NG1 5DD (GB)**

(54) **Peroxisome proliferator-activated receptor gamma ligand eluting medical device**

(57) Implantable medical devices having an anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) agonists are disclosed. The anti-restenotic PPAR $\gamma$  ligands include thiazolidinedione compounds including ciglitazone. The anti-restenotic medial devices include stents, catheters, micro-particles, probes and vascular grafts. The medical devices can be coated using any method known in the art including compounding the thiazolidin-

edione with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-thiazolidinedione blends are disclosed. Additionally, medical devices having a coating comprising at least one thiazolidinedione in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.

## Description

## FIELD OF THE INVENTION

[0001] The present invention relates generally to compositions and corresponding methods for preventing and/or treating restenosis in patients in need thereof. Specifically, the present invention relates to *in situ* peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) agonist delivery. More specifically, the present invention relates to PPAR $\gamma$  agonist eluting medical devices. In one embodiment of the present invention the medical devices include, without limitation, stents, catheters, micro-particles, probes and vascular grafts.

## BACKGROUND OF THE INVENTION

[0002] Cardiovascular disease, specifically atherosclerosis, remains a leading cause of death in developed countries. Atherosclerosis is a multifactorial disease that results in a narrowing, or stenosis, of a vessel lumen. Briefly, pathologic inflammatory responses resulting from vascular endothelium injury causes monocytes and vascular smooth muscle cells (VSMCs) to migrate from the sub endothelium and into the arterial wall's intimal layer. There the VSMC proliferate and lay down an extracellular matrix causing vascular wall thickening and reduced vessel patency.

[0003] Cardiovascular disease caused by stenotic coronary arteries is commonly treated using either coronary artery by-pass graft (CABG) surgery or angioplasty. Angioplasty is a percutaneous procedure wherein a balloon catheter is inserted into the coronary artery and advanced until the vascular stenosis is reached. The balloon is then inflated restoring arterial patency. One angioplasty variation includes arterial stent deployment. Briefly, after arterial patency has been restored, the balloon is deflated and a vascular stent is inserted into the vessel lumen at the stenosis site. The catheter is then removed from the coronary artery and the deployed stent remains implanted to prevent the newly opened artery from constricting spontaneously. However, balloon catheterization and stent deployment can result in vascular injury ultimately leading to VSMC proliferation and neointimal formation within the previously opened artery. This biological process whereby a previously opened artery becomes re-occluded is referred to as restenosis.

[0004] Treating restenosis requires additional, generally more invasive, procedures including CABG in some cases. Consequently, methods for preventing restenosis, or treating incipient forms, are being aggressively pursued. One possible method for preventing restenosis is the administration of medicaments that block local invasion/activation of monocytes thus preventing the secretion of growth factors that may trigger VSMC proliferation and migration. Metabolic inhibitors such as antineoplastic agents are currently being investigated as potential anti-restenotic compounds. However, the toxicity associated with the systemic administration of metabolic inhibitors has recently stimulated research into *in situ*, site-specific drug delivery.

[0005] Anti-restenotic coated stents are one potential method of site-specific drug delivery. Once the coated stent is deployed, it releases the anti-restenotic agent directly into the tissue thus allowing for clinically effective drug concentrations to be achieved locally without subjecting the recipient to side effects associated with systemic drug delivery. Moreover, localized delivery of anti-restenotic drugs results in anti-proliferative drug concentrations directly at the treatment thus eliminating the need for specific cell targeting technologies.

[0006] Recently, it has been reported that peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) agonists administered systemically can significantly reduce neointimal formation and VSMC proliferation at six-months after coronary stent implantation in patients with non-insulin dependent diabetes mellitus (Takagi, T. et al. 2000. J. Am. Col. Card. 36(5) 1529-1534). Peroxisome proliferator-activated receptor  $\gamma$  is a member of a nuclear receptor super family that is activated by ligands such as certain fatty acids, eicosanoids and insulin-sensitizing thiazolidinediones including rosiglitazone, pioglitazone, troglitazone, ciglitazone and others. (Jiang C. et al. 1998. Nature. 391: 82-85.) PPAR $\gamma$  agonists prevent vascular smooth muscle cell proliferation, migration and monocyte activation by inhibiting cyclin-dependent kinases (Law, R.E. et al. 1993. J. Clin. Invest. 98(8): 1897-1905 and Wakino, S. et al. 2000. J. Biol. Chem. 275(29): 22435-22441 and Kintscher et al. 2000. Eur. J. Pharm. 401(3) 259-270 and United States Patent Number 5,925,657 (the '657 patent)). Consequently, PPAR $\gamma$  agonists may prove valuable in treating and/or preventing restenosis.

[0007] Troglitazone, and other thiazolidinediones, are novel insulin-sensitizing agents that significantly reduce hyperinsulinemia and hyper-glycemia (Law, R.E. et al. 1993. J. Clin. Invest. 98(8): 1897-1905). However, systemic troglitazone blood levels required to treat non-insulin dependent diabetes have been associated with liver toxicity. Consequently, troglitazone has been withdrawn from the market as a treatment for type II diabetes. Moreover, the troglitazone plasma levels required to treat diabetes are the same as those needed to prevent restenosis systemically making it unlikely that thiazolidinediones will be useful as systemic anti-restenotics. Therefore, the development of an *in situ* thiazolidinediones delivery platform would represent a significant advance in the treatment and prevention of restenosis.

## SUMMARY OF THE INVENTION

[0008] The present invention provides an *in situ* drug delivery platform that can be used to administer anti-restenotic tissue levels of peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) agonist without systemic side effects. In one embodiment of the present invention the drug delivery platform is a medical device including, without limitations, stents, catheters, micro-particles, probes and vascular grafts.

[0009] In another embodiment of the present invention, a vascular stent is coated with thiazolidinedione PPAR $\gamma$  agonists. The thiazolidinediones can be attached to the vascular stent's surface using any means that provide a drug-releasing platform. Coating methods include, but are not limited to precipitation, coacervation, and crystallization. The thiazolidinediones of the present invention can be bound covalently, ionically, or through other intramolecular interactions including without limitation hydrogen bonding and van der Waals forces.

[0010] In another embodiment of the present invention the thiazolidinediones are complexed with a suitable biocompatible polymer. The polymer-drug complex is then used to either form a controlled-release medical device, integrated into a preformed medical device or used to coat a medical device. The biocompatible polymer may be any non-thrombogenic material that does not cause a clinically relevant adverse response. Suitable examples include, but are not limited to polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters, epoxies, silicones, cellulose and many others including co-polymers and blends thereof. Other methods of achieving controlled drug release are contemplated as being part of the present invention.

[0011] In another embodiment of the present invention the thiazolidinedione is selected from the non-limiting group consisting of 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione (rosiglitazone), (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl) methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone), 5-[p-[1-methylcyclohexyl)methoxyl]benzyl]-2,4-thiazolidinedione (ciglitazone), 5-[p-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[3-(5-methyl-2-phenyl-4-oxazolyl)propionyl]benzyl]-2,4-thiazolidinedione (darglitazone), 5-[[2R)-2-benzyl-6-chromanyl]methyl]-2,4-thiazolidinedione (englitazone), derivatives and combinations thereof. Moreover, the thiazolidinediones of the present invention can be combined with other anti-restenotic compounds including cytotoxic, cytostatic, anti-metabolic and anti-inflammatory compounds.

[0012] In yet another embodiment of the present invention an anti-restenotic compound coated stent can be combined with the local delivery of the same or another anti-restenotic compound to achieve a synergistic effect at the medical device placement site. This is particularly beneficial in that non-toxic therapeutic levels of both the thiazolidinediones and other anti-restenotic therapeutic can be combined to achieve dose specific synergism.

[0013] Additional embodiments of the present invention will be apparent to those skilled in the art from the detailed disclosure that follows.

## BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1a graphically depicts percent inhibition of Human Coronary Artery Smooth Muscle Cell (HCASMC) proliferation at various concentrations of Ciglitazone.

[0015] Figure 1b graphically depicts HCASMC cell counts at day 4 at various concentrations of Ciglitazone.

[0016] Figure 1c graphically depicts HCASMC cytotoxicity at various concentrations of Ciglitazone.

[0017] Figure 2a graphically depicts percent inhibition of Human Coronary Artery Endothelial Cell (HCAEC) proliferation at various concentrations of Ciglitazone.

[0018] Figure 2b graphically depicts HCAEC cell counts at day 4 at various concentrations of Ciglitazone.

[0019] Figure 2c graphically depicts HCAEC cytotoxicity at various concentrations of Ciglitazone.

[0020] Figure 3 graphically depicts HCASMC cell counts at day 4 at various concentrations of Rosiglitazone.


## DETAILED DESCRIPTION

[0021] In the detailed description and claims that follows the compounds used to prevent restenosis may be referred to herein or elsewhere as PPAR $\gamma$  agonists, thiazolidinediones, anti-restenotics, anti-restenotic compounds, drugs, therapeutics, anti-proliferatives, cytostatic agents, cytotoxic agents, or anti-metabolic agents. Furthermore, in the description and claims that follow, their trade name, chemical names or common names may refer to specific compounds. All of these terms may be used interchangeably without distinction and are all considered to within the scope of the present invention.

[0022] The present invention includes novel compositions and methods for delivering peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) agonists directly to tissues susceptible to restenosis. Specifically, the present invention is directed at implantable medical devices that provide for the *in situ*, site-specific controlled release of ligands that bind to and activate PPAR $\gamma$  receptors. Once activated, PPAR $\gamma$  receptors inhibit vascular smooth muscle cell (VSMC) proliferation.

**[0023]** In one embodiment of the present invention medical devices are provided with a PPAR  $\gamma$  agonist such as, but not limited to thiazolidinediones. Examples of PPAR  $\gamma$  agonist used in accordance with the teachings of the present invention include, but are not limited to 5-(4-[2-(N-methyl-N-(2-pyridyl)amino) ethoxy]benzyl)-2,4-thiazolidinedione (rosiglitazone), (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl) methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone), 5-[p-[1-methylcyclohexyl) methoxy]benzyl]-2,4-thiazolidinedione (ciglitazone), 5-[p-[2-(5-ethyl-2-pyridyl) ethoxy]benzyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[3-(5-methyl-2-phenyl-4-oxazolyl) propionyl]benzyl]-2,4-thiazolidinedione (darglitazone), and 5-[[[(2R)-2-benzyl-6-chromanyl]methyl]-2,4-thiazolidinedione (englitazone) (collectively referred to herein after as thiazolidinediones). Moreover, the present inventors also consider derivatives and analogous of the thiazolidinediones within the scope of the present invention.

**[0024]** Thiazolidinediones of the present invention share a common molecular backbone comprising the thiazolidinedione group:



**[0025]** Wherein R is a branched or straight chain alkyl group of from 1 to 20 carbons, a branched or straight chain alkenyl group of from 1 to 20 carbons, a substituted or un-substituted aryl group, a substituted or un-substituted heterocyclic group, a substituted or un-substituted heteroaromatic group and combinations thereof.

**[0026]** Furthermore, derivatives made by modifying the thiazolidinedione group itself are also considered to be within the scope of the present invention. Therefore, it can be seen to those having ordinary skill in the art of medicinal chemistry that thiazolidinedione derivatives in addition to the specific thiazolidinediones recited herein are contemplated to be within the scope of the present invention.

**[0027]** The thiazolidinediones and other PPAR $\gamma$  agonists of the present invention are delivered, alone or in combination with synergistic and/or additive therapeutic agents, directly to the affected area using medical devices. Potentially synergistic and/or additive therapeutic agents may include drugs that impact a different aspect of the restenosis process such as antiplatelet, antimigratory or antifibrotic agents. Alternately they may include drugs that also act as antiproliferatives and/or antiinflammatories but through a different mechanism than by binding to the PPAR $\gamma$  receptor. For example, and not intended as a limitation, synergistic combination considered to within the scope of the present invention include at least one thiazolidinedione and an antisense anti-c-myc oligonucleotide, at least one thiazolidinedione and rapamycin or analogues and derivatives thereof such as a 40-0-(2-hydroxyethyl)-rapamycin, at least one thiazolidinedione and Exochelin, at least one thiazolidinedione and n-acetyl cysteine inhibitors, at least one thiazolidinedione and geldanamycin and other chaperone inhibitors, and so one.

**[0028]** The medical devices used in accordance with the teachings of the present invention may be permanent medical implants, temporary implants, or removable devices. For examples, and not intended as a limitation, the medical devices of the present invention may include, stents, catheters, micro-particles, probes and vascular grafts.

**[0029]** In one embodiment of the present invention stents are used as the drug delivery platform. The stents may be vascular stents, urethral stents, biliary stents, or stents intended for use in other ducts and organ lumens. Vascular stents may be used in peripheral, neurological or coronary applications. The stents may be rigid expandable stents or pliable self expanding stents. Any biocompatible material may be used to fabricate the stents of the present invention including, without limitation, metals or polymers. The stents of the present invention may also be bioresorbable.

**[0030]** In one embodiment of the present invention vascular stents are implanted into coronary arteries immediately following angioplasty. However, one significant problem associated with stent implantation, specifically vascular stent deployment, is restenosis. Restenosis is a process whereby a previously opened lumen is re-occluded by VSMC proliferation. Therefore, it is an object of the present invention to provide stents that suppress or eliminate VSMC migration and proliferation and thereby reduce, and/or prevent restenosis.

**[0031]** In one embodiment of the present invention metallic vascular stents are coated with one or more anti-restenotic compound, specifically PPAR $\gamma$  agonists, more specifically the PPAR $\gamma$  agonists are thiazolidinediones. The thiazolidinediones may be dissolved or suspended in any carrier compound that provides a stable composition that does not react adversely with the device to be coated or inactivate the thiazolidinediones. The metallic stent is provided with a biologically active thiazolidinedione coating using any technique known to those skilled in the art of medical device manufacturing. Suitable non-limiting examples include impregnation, spraying, brushing, dipping and rolling. After the

thiazolidinedione solution is applied to the stent it is dried leaving behind a stable thiazolidinedione delivering medical device. Drying techniques include, but are not limited to heated forced air, cooled forced air, vacuum drying or static evaporation. Moreover, the medical device, specifically a metallic vascular stent, can be fabricated having grooves or wells in its surface that serve as receptacles or reservoirs for the thiazolidinedione compositions of the present invention.

[0032] The preferred concentration of PPAR $\gamma$  agonist used in accordance with the teachings of the present invention can be determined using a titration process. Titration is accomplished by preparing a series of stent sets. Each stent set will be coated, or contain different dosages of the PPAR $\gamma$  agonist selected. The highest concentration used will be partially based on the known toxicology of the compound. The maximum amount of drug delivered by the stents made in accordance with the teaching of the present invention will fall below known toxic levels. Each stent set will be tested in vivo using the preferred animal model as described in Example 5 below. The dosage selected for further studies will be the minimum dose required to achieve the desired clinical outcome. In the case of the present invention, the desired clinical outcome is defined as the inhibition of vascular re-occlusion, or restenosis.

[0033] In another embodiment the thiazolidinediones are precipitated or crystallized on or within the stent. In yet another embodiment the thiazolidinediones are mixed with a suitable biocompatible polymer (bioerodable, bioresorbable or non-erodable) such as, but not limited to polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters, epoxies, silicones, cellulose and many others including blends thereof. The polymer-thiazolidinedione blend can then be used to produce a medical device such as, but not limited to stents, grafts, micro-particles, sutures and probes. Furthermore, the polymer-thiazolidinedione blend can be used to coat medical device surfaces. For example, and not intended as a limitation, the medical device can be immersed in the polymer-thiazolidinedione blend, or the polymer-thiazolidinedione blend can be sprayed, or brushed onto the medical device. In another embodiment, the polymer-thiazolidinedione blend can be used to fabricate fibers or strands that are embedded into the medical device or used to wrap the medical device.

[0034] Controlled *in situ* release of thiazolidinedione compositions of the present invention can be achieved using a variety of techniques known to those skilled in the art. For example, the polymer-thiazolidinedione blends of the present invention can be designed such that the polymer absorption rate dictates drug release. In one embodiment of the present invention a polycaprolactone-ciglitazone blend is prepared. A metallic vascular stent is then stably coated with polymer-blend wherein the stent coating has a thickness of between approximately 0.1  $\mu\text{m}$  to approximately 100  $\mu\text{m}$ . The polymer coating thickness determines the total amount of ciglitazone delivered and the polymer's absorption rate of polycaprolactone determines the administration rate. Using this example, it is possible for one of ordinary skill in the part of polymer chemistry to design coatings having a wide range of dosages and administration rates. Furthermore, drug delivery rates and concentrations can also be controlled using non-polymer containing coatings and techniques known to persons skilled in the art of medicinal chemistry and medical device manufacturing.

[0035] The following examples are provided to more precisely define and enable the PPAR $\gamma$  agonist-eluting medical devices of the present invention. It is understood that there are numerous other embodiments and methods of using the present invention that will be apparent to those of ordinary skill in the art after having read and understood this specification and examples. These alternate embodiments are considered part of the present invention.

## EXAMPLES

### Providing a Metallic Surface with a PPAR $\gamma$ agonist-eluting Coating

[0036] The following Examples are intended to illustrate a non-limiting process for coating metallic stents with a PPAR $\gamma$  agonist and testing their anti-restenotic properties. One non-limiting example of a metallic stent suitable for use in accordance with the teachings of the present invention is the Medtronic/AVE S670™ 316L stainless steel coronary stent.

## EXAMPLE 1

### Metal Stent Cleaning Procedure

[0037] Stainless steel stents were placed a glass beaker and covered with reagent grade or better hexane. The beaker containing the hexane immersed stents was then placed into an ultrasonic water bath and treated for 15 minutes at a frequency of between approximately 25 to 50 KHz. Next the stents were removed from the hexane and the hexane was discarded. The stents were then immersed in reagent grade or better 2-propanol and vessel containing the stents and the 2-propanol was treated in an ultrasonic water bath as before. Following cleaning the stents with organic solvents, they were thoroughly washed with distilled water and thereafter immersed in 1.0 N sodium hydroxide solution and treated at in an ultrasonic water bath as before. Finally, the stents were removed from the sodium hydroxide, thoroughly rinsed in distilled water and then dried in a vacuum oven over night at 40°C.

[0038] After cooling the dried stents to room temperature in a desiccated environment they were weighed their weights were recorded.

## EXAMPLE 2

### Coating a Clean, Dried Stent Using a Drug/polymer System

[0039] 250 mg of ciglitazone was carefully weighed and added to a small neck glass bottle containing 27.56 ml of tetrahydrofuran (THF). The ciglitazone-THF suspension was then thoroughly mixed until a clear solution is achieved.

[0040] Next 251.6 mg of polycaprolactone (PCL) was added to the ciglitazone-THF solution and mixed until the PCL dissolved forming a drug/polymer solution.

[0041] The cleaned, dried stents were coated using either spraying techniques or dipped into the drug/polymer solution. The stents were coated as necessary to achieve a final coating weight of between approximately 10 µg to 1 mg. Finally, the coated stents were dried in a vacuum oven at 50°C over night. The dried, coated stents were weighed and the weights recorded.

[0042] The concentration of drug loaded onto (into) the stents was determined based on the final coating weight. Final coating weight is calculated by subtracting the stent's pre-coating weight from the weight of the dried, coated stent.

## EXAMPLE 3

### Coating a Clean, Dried Stent Using a Sandwich-type Coating

[0043] A cleaned, dry stent was first coated with polyvinyl pyrrolidone (PVP) or another suitable polymer followed by a coating of ciglitazone. Finally, a second coating of PVP was provided to seal the stent thus creating a PVP-ciglitazone-PVP sandwich coated stent.

The Sandwich Coating Procedure:

[0044] 100.2 mg of PVP was added to a 50 mL Erlenmeyer containing 12.5 ml of methanol. The flask was carefully mixed until all of the PVP is dissolved. In a separate clean, dry Erlenmeyer flask 252 mg of ciglitazone was added to 11 mL of THF and mixed until dissolved.

[0045] A clean, dried stent was then sprayed with PVP until a smooth confluent polymer layer was achieved. The stent was then dried in a vacuum oven at 50°C for 30 minutes.

[0046] Next the nine successive layers of the ciglitazone were applied to the polymer-coated stent. The stent was allowed to dry between each of the successive ciglitazone coats. After the final ciglitazone coating had dried, three successive coats of PVP were applied to the stent followed by drying the coated stent in a vacuum oven at 50°C over night. The dried, coated stent is weighed and its weight recorded.

[0047] The concentration of drug in the drug/polymer solution and the final amount of drug loaded onto the stent determine the final coating weight. Final coating weight is calculated by subtracting the stent's pre-coating weight from the weight of the dried, coated stent.

## EXAMPLE 4

### Coating a Clean, Dried Stent with Pure Drug

[0048] 1.007 g of ciglitazone was carefully weighed and added to a small neck glass bottle containing 11.4 ml of ethyl alcohol (EtOH). The ciglitazone-EtOH suspension was then heated at 50°C for 15 minutes and then mixed until the ciglitazone was completely dissolved.

[0049] Next a clean, dried stent was mounted over the balloon portion of angioplasty balloon catheter assembly. The stent was then sprayed with, or in an alternative embodiment, dipped into, the ciglitazone-EtOH solution. The coated stent was dried in a vacuum oven at 50°C over night. The dried, coated stent was weighed and its weight recorded.

[0050] The concentration of drug loaded onto (into) the stents was determined based on the final coating weight. Final coating weight is calculated by subtracting the stent's pre-coating weight from the weight of the dried, coated stent.

**EXAMPLE 5****In vivo Testing of a PPAR  $\gamma$  agonist-coated Vascular Stent in a Porcine Model**

5   **[0051]** The ability of a PPAR  $\gamma$  agonist to reduce neointimal hyperplasia in response to intravascular stent placement in an acutely injured porcine coronary artery is demonstrated in the following example. Two controls and three treatment arms were used as outlined below:

10   1. Control Groups:

**[0052]** Six animals were used in each control group. The first control group tests the anti-restenotic effects of the clean, dried stent having neither polymer nor drug coatings. The second control group tests the anti-restenotic effects of polymer alone. Clean, dried stents having PCL coatings without drug were used in the second control group.

15   2. Experimental Treatment Groups

**[0053]** Three different stent configurations and two different drug dosages are evaluated for their anti-restenotic effects. Twelve animals are included in each group.

20   **[0054]** Group 1 stents are designated the fast release group and are comprised of 50  $\mu$ g ciglitazone coated onto a bare stent without polymer in accordance with the teachings of the present invention.

**[0055]** Group 2, designated the slow-release group, uses stents coated with 50  $\mu$ g of ciglitazone impregnated within a polymer at a ciglitazone to polymer ratio of 1:9 in accordance with the teachings of the present invention.

**[0056]** Group 3, designated the medium-release group, uses stents coated with 250  $\mu$ g of ciglitazone impregnated within a polymer at a ciglitazone to polymer ratio of 1:1 in accordance with the teachings of the present invention.

25   **[0057]** The swine has emerged as the most appropriate model for the study of the endovascular devices. The anatomy and size of the coronary vessels are comparable to that of humans. Furthermore, the neointimal hyperplasia that occurs in response to vascular injury is similar to that seen clinically in humans. Results obtained in the swine animal model are considered predictive of clinical outcomes in humans. Consequently, regulatory agencies have deemed six-month data in the porcine sufficient to allow progression to human trials.

30   **[0058]** Non-atherosclerotic acutely injured RCA, LAD, and/or LCX arteries of the Farm Swine (or miniswine) are utilized in this study. Placement of coated and control stents is random by animal and by artery. The animals are handled and maintained in accordance with the requirements of the Laboratory Animal Welfare Act (P.L.89-544) and its 1970 (P.L. 91-579), 1976 (P.L. 94-279), and 1985 (P.L. 99-198) amendments. Compliance is accomplished by conforming to the standards in the Guide for the Care and the Use of Laboratory Animals, ILAR, National Academy Press, revised 1996. A veterinarian performs a physical examination on each animal during the pre-test period to ensure that only healthy pigs are used in this study.

A. Pre-Operative Procedures

40   **[0059]** The animals are monitored and observed 3 to 5 days prior to experimental use. The animals have their weight estimated at least 3 days prior to the procedure in order to provide appropriate drug dose adjustments for body weight. At least one day before stent placement, 650mg of aspirin is administered. Animals are fasted twelve hours prior to the procedure.

45   B. Anesthesia

**[0060]** Anesthesia is induced in the animal using intramuscular Telazol and Xylazine. Atropine is administered (20  $\mu$ g/kg I.M.) to control respiratory and salivary secretions. Upon induction of light anesthesia, the subject animal is intubated. Isoflurane (0.1 to 5.0% to effect by inhalation) in oxygen is administered to maintain a surgical plane of anesthesia. Continuous electrocardiographic monitoring is performed. An I.V. catheter is placed in the ear vein in case it is necessary to replace lost blood volume. The level of anesthesia is monitored continuously by ECG and the animal's response to stimuli.

55   C. Catheterization and Stent Placement

**[0061]** Following induction of anesthesia, the surgical access site is shaved and scrubbed with chlorohexidine soap. An incision is made in the region of the right or left femoral (or carotid) artery and betadine solution is applied to the surgical site. An arterial sheath is introduced via an arterial stick or cutdown and the sheath is advanced into the artery.

A guiding-catheter is placed into the sheath and advanced via a 0.035" guide wire as needed under fluoroscopic guidance into the ostium of the coronary arteries. An arterial blood sample is obtained for baseline blood gas, ACT and HCT. Heparin (200 units/kg) is administered as needed to achieve and maintain ACT  $\geq$  300 seconds. Arterial blood pressure, heart rate, and ECG are recorded.

[0062] After placement of the guide catheter into the ostium of the appropriate coronary artery, angiographic images of the vessels are obtained in at least two orthogonal views to identify the proper location for the deployment site. Quantitative coronary angiography (QCA) is performed and recorded. Nitroglycerin (200  $\mu$ g I.C.) is administered prior to treatment and as needed to control arterial vasospasm. The delivery system is prepped by aspirating the balloon with negative pressure for five seconds and by flushing the guidewire lumen with heparinized saline solution.

[0063] Deployment, patency and positioning of stent are assessed by angiography and a TIMI score is recorded. Results are recorded on video and cine. Final lumen dimensions are measured with QCA and/or IVUS. These procedures are repeated until a device is implanted in each of the three major coronary arteries of the pig. After final implant, the animal is allowed to recover from anesthesia. Aspirin is administered at 325 mg p.o. qd until sacrifice.

#### D. Follow-up Procedures and Termination

[0064] After 28 days, the animals are anesthetized and a 6F arterial sheath is introduced and advanced. A 6F large lumen guiding-catheter (diagnostic guide) is placed into the sheath and advanced over a guide wire under fluoroscopic guidance into the coronary arteries. After placement of the guide catheter into the appropriate coronary ostium, angiographic images of the vessel are taken to evaluate the stented sites. At the end of the re-look procedure, the animal is euthanized with an overdose of Pentobarbital I.V. and KCL I.V. The heart, kidneys, and liver are harvested and visually examined for any external or internal trauma. The organs are flushed with 1000 ml of lactated ringers at 100 mmHg and then flushed with 1000 ml of formalin at 100-120 mmHg. All organs are stored in labeled containers of formalin solution.

#### E. Histology and Pathology

[0065] The stented vessels will be X-rayed prior to histology processing. The stented segments are processed for routine histology, sectioned, and stained following standard histology lab protocols. Appropriate stains are applied in alternate fashion on serial sections through the length of the treated vessels.

#### F. Data Analysis and Statistics

##### 1. QCA Measurement

[0066] Quantitative angiography is performed to measure the balloon size at peak inflation as well as vessel diameter pre- and post-stent placement and at the 28 day follow-up. The following data are measured or calculated from angiographic data:

Stent-to-artery-ratio  
Minimum lumen diameter (MLD)  
Distal and proximal reference lumen diameter

$$\text{Percent Stenosis} = (\text{Minimum lumen diameter} + \text{reference lumen diameter}) \times 100$$

##### 2. Histomorphometric analysis

[0067] Histologic measurements are made from sections from the native proximal and distal vessel and proximal, middle, and distal portions of the stent. A vessel injury score is calculated using the method described by Schwartz et al. (Schwartz RS et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992;19:267-74). The mean injury score for each arterial segment is calculated. Investigators scoring arterial segment and performing histopathology are "blinded" to the device type. The following measurements are determined:

External elastic lamina (EEL) area  
Internal elastic lamina (IEL) area  
Luminal area

Adventitial area  
Mean neointimal thickness  
Mean injury score

3. The neointimal area and the % of in-stent restenosis are calculated as follows:

[0068]

Neointimal area = (IEL-luminal area)

In-stent restenosis =  $[1 - (\text{luminal area} + \text{IEL})] \times 100$ .

[0069] A given treatment arm will be deemed beneficial if treatment results in a significant reduction in neointimal area and/or in-stent restenosis compared to both the bare stent control and the polymer-on control.

G. Surgical Supplies and Equipment

[0070] The following surgical supplies and equipment are required for the procedures described above:

1. Standard vascular access surgical tray
2. Non-ionic contrast solution
3. ACT machine and accessories
4. HCT machine and accessories (if applicable)
5. Respiratory and hemodynamic monitoring system
6. IPPB Ventilator, associated breathing circuits and Gas Anesthesia Machine
7. Blood gas analysis equipment
8. 0.035" HTF or Wholey modified J guidewire, 0.014" Guidewires
9. 6, 7, 8, and 9F introducer sheaths and guiding catheters (as applicable)
10. Cineangiography equipment with QCA capabilities
11. Ambulatory defibrillator
12. Standard angioplasty equipment and accessories
13. IVUS equipment (if applicable)
14. For radioactive labeled cell studies (if applicable):
15. Centrifuge
16. Aggregometer
17. Indium 111 oxime or other as specified
18. Automated Platelet Counter
19. Radiation Detection Device

#### EXAMPLE 6

##### Inhibition of Human Coronary Artery Smooth Muscle Cells by Ciglitazone

###### A. Materials

[0071]

1. Human coronary smooth muscles cells (HCASMC) were obtained from Clonetics, a division of Cambrex, Inc.
2. HCASMC basal Media, supplied by Clonetics and supplemented with fetal bovine serum, insulin, hFGF-B (human fibroblast growth factor) hEGF (human epidermal growth factor).
3. Ciglitazone Sigma Chemical Company catalogue number C-3974
4. Absolute Ethanol
5. Twenty-four well polystyrene tissue culture plates

###### B. Human coronary artery smooth muscle cells proliferation inhibition studies.

[0072] Human coronary smooth muscles cells (HCASMC) were seeded in 24 well polystyrene tissue culture plates at a density of  $5 \times 10^3$  cells per well. Two different feeding and reading strategies were employed. Strategy 1: Cells were plated in cell culture media containing various concentrations of Ciglitazone and incubated at 37° C for 48 hours.

After the initial 48 hour incubation, the Ciglitazone containing plating media was changed and the cells were fed with drug free media and incubated for an additional 48 hours and then read.

[0073] Strategy 2: Cells were plated in cell culture media containing various concentrations of Ciglitazone and incubated at 37° C for 48 hours. After the initial 48 hour incubation, the Ciglitazone-containing plating media was changed and the cells were fed with Ciglitazone-containing media and incubated for an additional 48 hours and then read.

[0074] On day four cultures were analyzed to determine the proliferation inhibition effects of Ciglitazone. FIG. 1a graphically depicts the percent inhibition at Ciglitazone levels between 0.001 µg/mL to 50 µg/mL for both cell culture schemes. It can be seen from FIG 1a that significant HCASMC inhibition (>50% inhibition) begins at a dosage of 10 µg/mL and rises dramatically to nearly 100% at 50 µg/mL. FIG. 1b graphically depicts the same results in bar graph form based on cell counts.

#### C. Ciglitazone Cytotoxicity Testing

[0075] Ciglitazone cytotoxicity against HCASMCs was evaluated by seeding 24 well cell culture plates with  $5.0 \times 10^5$  HCASMC cells/mL of cell culture media containing from 0.001 µg/mL to 10 µg/mL of Ciglitazone. Samples were taken after 24 hours and tested for lactate dehydrogenase (LDL) concentration using methods known to those having ordinary skill in the art. Elevated LDL levels indicates cytotoxicity. FIG. 1c graphically depicts the cytotoxicity testing results. No cytotoxicity was detected at Ciglitazone concentrations that demonstrated significant anti-proliferative effects.

#### EXAMPLE 7

##### Inhibition of Human Coronary Artery Endothelial Cells by Ciglitazone

#### A. Materials

##### [0076]

1. Human coronary artery endothelial cells (HCAEC) were obtained from Clonetics, a division of Cambrex, Inc.
2. HCAEC basal Media, supplied by Clonetics and supplemented with fetal bovine serum, VEGF (vascular endothelial growth factor) hEGF heparin, ascorbic acid IGF (insulin growth factor) hydrocortisone
3. Ciglitazone Sigma Chemical Company catalogue number C-3974
4. Absolute Ethanol
5. Twenty-four well polystyrene tissue culture plates

#### B. Human coronary smooth muscles cells proliferation inhibition studies.

[0077] Human coronary artery endothelial cells (HCAEC) were seeded in 24 well polystyrene tissue culture plates at a density of  $5 \times 10^3$  cells per well. Two different feeding strategies and reading strategies were employed. Strategy 1: Cells were plated in cell culture media containing various concentrations of Ciglitazone and incubated at 37° C for 48 hours. After the initial 48 hour incubation, the Ciglitazone containing plating media was changed and the cells were fed with drug free media and incubated for an additional 48 hours and then read.

[0078] Strategy 2: Cells were plated in cell culture media containing various concentrations of Ciglitazone and incubated at 37° C for 48 hours. After the initial 48 hour incubation, the Ciglitazone-containing plating media was changed and the cells were fed with Ciglitazone-containing media and incubated for an additional 48 hours and then read.

[0079] On day four cultures were analyzed to determine the proliferation inhibition effects of Ciglitazone. FIG. 1a graphically depicts the percent inhibition at Ciglitazone levels between 0.001 µg/mL to 50 µg/mL for both cell culture schemes. It can be seen from FIG 2a that significant HCAEC inhibition (>50% inhibition) begins at a dosage of 5 µg/mL and rises dramatically to nearly 100% at 10 µg/mL. FIG. 2b graphically depicts the same results in bar graph form based on cell counts.

#### C. Ciglitazone Cytotoxicity Testing

[0080] Ciglitazone cytotoxicity against HCAECs was evaluated by seeding 24 well cell culture plates with  $5.0 \times 10^5$  HCAEC cells/mL of cell culture media containing from 0.001 µg/mL to 10 µg/mL of Ciglitazone. Samples were taken after 24 hours and tested for lactate dehydrogenase (LDL) concentration using methods known to those having ordinary skill in the art. Elevated LDL levels indicate cytotoxicity. FIG. 2c graphically depicts the cytotoxicity testing results. No cytotoxicity was detected at Ciglitazone concentrations that demonstrated significant anti-proliferative effects.

**EXAMPLE 8****Inhibition of Human Coronary Artery Smooth Muscle Cells by Rosiglitazone****A. Materials****[0081]**

1. Human coronary smooth muscles cells (HCASMC) were obtained from Clonetics, a division of Cambrex, Inc.
2. HCASMC basal Media, supplied by Clonetics and supplemented with fetal bovine serum, insulin, hFGF-B (human fibroblast growth factor) hEGF (human epidermal growth factor).
3. Rosiglitazone Sigma Chemical Company
4. Absolute Ethanol
5. Twenty-four well polystyrene tissue culture plates

**B. Human coronary smooth muscles cells proliferation inhibition studies.**

**[0082]** Human coronary smooth muscles cells (HCASMC) were seeded in 24 well polystyrene tissue culture plates at a density of  $5 \times 10^3$  cells per well. Two different feeding strategies and reading strategies were employed. Strategy 1: Cells were plated in cell culture media containing various concentrations of Rosiglitazone and incubated at 37° C for 48 hours. After the initial 48 hour incubation, the Rosiglitazone containing plating media was changed and the cells were fed with drug free media and incubated for an additional 48 hours and then read.

**[0083]** Strategy 2: Cells were plated in cell culture media containing various concentrations of Rosiglitazone and incubated at 37° C for 48 hours. After the initial 48 hour incubation, the Rosiglitazone-containing plating media was changed and the cells were fed with Rosiglitazone-containing media and incubated for an additional 48 hours and then read.

**[0084]** On day four cultures were analyzed to determine the proliferation inhibition effects of Rosiglitazone. FIG. 3 graphically depicts Rosiglitazone inhibition of HCASMC in bar graph form based on cell counts. Rosiglitazone levels between 0.001 µg/mL to 100 µg/mL for both cell culture schemes.

**[0085]** Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

**[0086]** The terms "a" and "an" and "the" and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. "such as") provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.

**[0087]** Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

**[0088]** Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on those preferred embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such

variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

[0089] Furthermore, numerous references have been made to patents and printed publications throughout this specification. Each of the above cited references and printed publications are herein individually incorporated by reference.

[0090] In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.

## Claims

1. A medical device comprising a site-specific delivery device for at least one peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) agonist.
2. The medical device according to claim 1 wherein said PPAR $\gamma$  agonist is a thiazolidinedione.
3. The medical device according to claim 2 wherein said thiazolidinedione is selected from the group consisting of 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione (rosiglitazone), (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl) methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone), 5-[p-[1-methylcyclohexyl) methoxyl]benzyl]-2,4-thiazolidinedione (ciglitazone), 5-[p-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione (pioglitazone), 5-[p-[3-(5-methyl-2-phenyl-4-oxazolyl) propionyl]benzyl]-2,4-thiazolidinedione (darglitazone), 5-[[[(2R)-2-benzyl-6-chromanyl]methyl]-2,4-thiazolidinedione (englitazone), derivatives thereof and combinations thereof.
4. The medical device according to claim 1 wherein said PPAR $\gamma$  agonist is ciglitazone.
5. The medical device according to any of claims 1, 2, 3 or 4 wherein said medical device is selected from the group consisting of stents, catheters, micro-particles, probes and vascular grafts.
6. The medical device according to claim 5 wherein said stent is a vascular stent or biliary stent.
7. The medical device according to claim 6 wherein said vascular stent is provided with a coating comprising at least one thiazolidinedione.
8. The medical device according to claim 7 wherein said thiazolidinedione is selected from the group consisting of rosiglitazone, pioglitazone, troglitazone, darglitazone, englitazone, ciglitazone, derivatives thereof and combinations thereof.
9. The medical device according to claim 8 wherein said coating further contains a biocompatible polymer selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.
10. A vascular stent having a coating comprising ciglitazone.
11. A medical device comprising a stent having a coating comprising at least one thiazolidinedione selected from the group consisting of rosiglitazone, pioglitazone, troglitazone, darglitazone, englitazone, ciglitazone, derivatives thereof and combinations thereof; and  
a polymer selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.
12. The medical device according to claim 11 wherein said coating comprises:

between approximately 50 µg to 250 µg of ciglitazone and polycaprolactone, wherein said ciglitazone and said polycaprolactone are in a ratio relative to each other of approximately 1 part ciglitazone to approximately between 1 to 9 parts polycaprolactone.

13. A method of treating or inhibiting restenosis comprising:

providing a vascular stent having a coating comprising at least one PPAR $\gamma$  agonist; and  
implanting said vascular stent into a blood vessel lumen wherein said PPAR $\gamma$  agonist is released into tissue adjacent said blood vessel lumen.

14. The method according to claim 13 wherein said PPAR $\gamma$  agonist is a thiazolidinedione.

15. The method according to claim 14 wherein said thiazolidinedione is selected from the group consisting of rosiglitazone, pioglitazone, troglitazone, darglitazone, englitazone, ciglitazone, derivatives thereof and combinations thereof.

16. The method according to claim 13 wherein said coating comprises ciglitazone.

17. The method according to claim 13 wherein said coating comprises:

between approximately 50 µg to 250 µg of ciglitazone and polycaprolactone, wherein said ciglitazone and said polycaprolactone are in a ratio relative to each other of approximately 1 part ciglitazone to approximately between 1 to 9 parts polycaprolactone.

18. A method for producing a medical device comprising:

providing medical device to be coated;  
compounding at least one thiazolidinedione selected from the group consisting of rosiglitazone, pioglitazone, troglitazone, darglitazone, englitazone, ciglitazone, derivatives thereof and combinations thereof with a carrier compound; and  
coating said medical devices with said thiazolidinedione compounded with said carrier compound.

19. The method according to claim 18 wherein said medical device is a vascular stent.

20. The method according to claim 18 further wherein said carrier compound is a biocompatible polymer selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, caprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.

21. A medical device comprising a stent having a coating comprising at least one thiazolidinedione selected from the group consisting of rosiglitazone, pioglitazone, troglitazone, darglitazone, englitazone, ciglitazone, derivatives thereof and combinations thereof; and

at least one additional therapeutic agent selected from the group consisting of antiplatelet agents, antimigratory agent, antifibrotic agents, antiproliferatives, antiinflammatories and combinations thereof providing that said additional therapeutic agent is not a PPAR $\gamma$  agonist.

22. The medical device according to claim 21 wherein said at least one additional therapeutic agent is selected from the group consisting of antisense oligonucleotides, rapamycin, analogues of rapamycin, exochelin, n-acetyl cysteine inhibitors, chaperone inhibitors and combinations thereof.

23. The medical device according to claim 22 wherein said antisense oligonucleotide is an anti-c-myc oligonucleotide.

24. The medical device according to claim 22 wherein said chaperone inhibitor is geldanamycin.

25. The medical device according to claim 22 wherein said rapamycin derivative is 40-O-(2-hydroxyethyl)-rapamycin.

26. A method of treating or inhibiting restenosis comprising:

**EP 1 236 478 A1**

providing a vascular stent having a coating comprising at least one PPAR $\gamma$  agonist and at least one additional therapeutic agent selected from the group consisting of antiplatelet agents, antimigratory agent, antifibrotic agents, antiproliferatives, antiinflammatories and combinations thereof providing that said additional; therapeutic agent is not a PPAR $\gamma$  agonist; and

implanting said vascular stent into a blood vessel lumen wherein said least one PPAR $\gamma$  agonist and at least one additional therapeutic agent are released into tissue adjacent to said blood vessel lumen.

5

10

15

20

25

30

35

40

45

50

55




Figure 1a




Figure 1b




Figure 1c




Figure 2a




Figure 2b




Figure 2c




Figure 3



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 02 25 1370

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CL.7)
X,P	WO 01 62238 A (SAN DIEGO STATE UNIVERSITY) 30 August 2001 (2001-08-30) * page 5, line 22 - line 30 * * page 16, line 24 - line 30 * * page 22, line 29 - line 32 *	1-5	A61L29/16 A61L29/08 A61L31/10 A61L31/16
X	US 5 925 657 A (JIANG CHENGYU ET AL) 20 July 1999 (1999-07-20) * column 2, line 19 - line 27; figure 12 * * column 7, line 17 - line 29 *	1-3	
Y	US 5 866 595 A (PERSHADSINGH HARRIHAR A ET AL) 2 February 1999 (1999-02-02) * abstract *	1-26	
Y	WO 99 48529 A (WARNER LAMBERT CO (US)) 30 September 1999 (1999-09-30) * page 1, line 3 - page 2, line 31 *	1-26	
-/--			
			TECHNICAL FIELDS SEARCHED (Int.CL.7)
			A61L A61K
<b>INCOMPLETE SEARCH</b>			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p style="text-align: center;">see sheet C</p>			
Place of search		Date of completion of the search	Examiner
MUNICH		20 June 2002	Leutner, S
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.02 (P04027)



European Patent  
Office

**INCOMPLETE SEARCH  
SHEET C**

Application Number  
EP 02 25 1370

Although claims 13-17 and 26 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

-----

Claim(s) searched completely:  
1-12, 18-25

Claim(s) searched incompletely:  
13-17, 26

Reason for the limitation of the search (non-patentable invention(s)):

Article 52 (4) EPC - Method for treatment of the human or animal body by therapy



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 02 25 1370

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	LINCOFF A MICHAEL ET AL: "Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model." JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 29, no. 4, 1997, pages 808-816, XP002202663 ISSN: 0735-1097 * the whole document *	1-26	
Y	BRIEGER DAVID ET AL: "Local drug delivery systems and prevention of restenosis." CARDIOVASCULAR RESEARCH, vol. 35, no. 3, 1997, pages 405-413, XP002202664 ISSN: 0008-6363 * page 410, paragraph 3.3. *	1-26	TECHNICAL FIELDS SEARCHED (Int.Cl.7)

EPO FORM 1503 02.82 (P04C10)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 25 1370

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-06-2002

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0162238	A	30-08-2001	AU	4723301 A	03-09-2001
			WO	0162238 A2	30-08-2001
			US	2002006942 A1	17-01-2002
<hr/>					
US 5925657	A	20-07-1999	AU	8147198 A	04-01-1999
			WO	9857631 A1	23-12-1998
<hr/>					
US 5866595	A	02-02-1999	NONE		
<hr/>					
WO 9948529	A	30-09-1999	AU	1707599 A	18-10-1999
			WO	9948529 A1	30-09-1999
<hr/>					

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82